Jeanie J Ahn, MD
Nephrology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 5 carriers
- Office
- 1
- Since medical school
- 30 years
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 1996
Offices
1 location · West Coast Kidney · 56 clinicians in this group
Looking this up.
Hospitals listed: 552698 · Highland Hospital · St Rose Hospital · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
20 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ahn’s office at (510) 745-8187 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A65315 · Current
Licensed to practise in California · since 1998 · expires 2028-01-31 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
- St Rose HospitalHayward, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency departmentPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
See every measure and the patient survey for St Rose Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 3 the same, 2 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 227 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.57 to 1.47) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 11 · 57 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.2 · 62 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 20.6 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 567 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.09 to 0.54) · 1,834 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,870 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.71 (1.17 to 6.25) · 285 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.13 (0.4 to 3.87) · 124 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.23 (0.53 to 3.92) · 295 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.87 (1.85 to 21.89) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.19 (0.86 to 9.51) · 120 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.27) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.36 (0 to 1.39) · 1,264 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 97 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.563 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 120 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35 · 116 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 29.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.8 · 147 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 101 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
What patients said (389 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$287,511
Medicare paid this office $287,511 for 521 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $88,812 | $313 |
| Long return visit (40+ min) | 127 | $36,147 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 152 | $33,943 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 173 | $24,523 | $69 |
| Return visit (30+ min) | 125 | $23,240 | $107 |
See all 17 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $88,812 | $313 |
| Long return visit (40+ min) | 127 | $36,147 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 152 | $33,943 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 173 | $24,523 | $69 |
| Return visit (30+ min) | 125 | $23,240 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 91 | $15,146 | $153 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | $9,582 | $259 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 39 | $9,472 | $59 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 211 | $6,793 | $14 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 40 | $5,244 | $46 |
| Hemodialysis procedure with physician evaluation | 50 | $4,809 | $62 |
| Telephone medical discussion with physician, 21-30 minutes | 32 | $4,701 | $107 |
| New patient visit (60+ min) | 26 | $4,424 | $170 |
| New patient visit (45+ min) | 23 | $3,325 | $145 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $2,877 | $107 |
| Short return visit (20+ min) | 24 | $1,964 | $70 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 27 | $1,340 | $43 |
Who their Medicare patients are
521 Original Medicare patients in 2024. Average age 76 · Under 65 11% · 85 and older 25% · Women 53% · Also on Medicaid 68% · Health risk score 4.06. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 72% · Coronary heart disease 55% · Heart failure 53% · Atrial fibrillation 37% · COPD 26% · Dementia 25% · Depression 23% · Stroke 20% · Cancer 17%.
The office billed $765,839, Medicare allowed $376,365 and paid $287,511; for 2,685 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 521 | 2,685 | 76 | 4.06 | $765,839 | $287,511 |
| 2023 | 514 | 1,821 | 77 | 4.02 | $659,668 | $249,837 |
| 2022 | 527 | 2,022 | 76 | 3.80 | $665,271 | $233,147 |
| 2021 | 409 | 1,836 | 76 | 3.57 | $605,562 | $239,346 |
| 2020 | 404 | 1,988 | 75 | 3.80 | $601,685 | $233,701 |
| 2019 | 441 | 2,302 | 76 | 3.77 | $673,100 | $257,035 |
| 2018 | 447 | 2,002 | 75 | 3.59 | $632,105 | $231,918 |
| 2017 | 472 | 2,233 | 74 | 3.77 | $648,355 | $247,578 |
| 2016 | 437 | 2,040 | 75 | 4.03 | $591,932 | $233,407 |
| 2015 | 434 | 2,024 | 74 | 3.84 | $590,178 | $235,500 |
| 2014 | 382 | 1,793 | 74 | 3.69 | $494,215 | $202,066 |
| 2013 | 432 | 2,245 | 74 | 4.20 | $572,601 | $239,614 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 39 | $93,764 | $324 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 160 | $36,700 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 168 | $25,267 | $71 |
| Long return visit (40+ min) | 111 | $22,402 | $107 |
| Return visit (30+ min) | 124 | $21,638 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $16,206 | $156 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $6,237 | $271 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,825 | $118 |
| Hemodialysis procedure with physician evaluation | 42 | $3,939 | $65 |
| Short return visit (20+ min) | 37 | $3,465 | $75 |
| New patient visit (60+ min) | 17 | $3,296 | $194 |
| New patient visit (45+ min) | 12 | $1,740 | $145 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $1,290 | $44 |
2022: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 36 | $82,306 | $322 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 192 | $29,843 | $62 |
| Return visit (30+ min) | 132 | $21,733 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 129 | $21,580 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 101 | $18,701 | $175 |
| Long return visit (40+ min) | 80 | $15,651 | $84 |
| Hemodialysis procedure with physician evaluation | 54 | $7,163 | $63 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 20 | $5,781 | $263 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $5,004 | $116 |
| New patient visit (45+ min) | 29 | $3,749 | $129 |
| Short return visit (20+ min) | 46 | $3,422 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 48 | $1,924 | $33 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $848 | $61 |
2021: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 34 | $78,110 | $325 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 129 | $31,840 | $66 |
| Long return visit (40+ min) | 97 | $29,142 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $23,111 | $93 |
| Return visit (30+ min) | 117 | $20,884 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $13,581 | $176 |
| Hemodialysis procedure with physician evaluation | 38 | $6,261 | $65 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $5,768 | $275 |
| New patient visit (60+ min) | 20 | $4,125 | $206 |
| New patient visit (45+ min) | 29 | $4,074 | $140 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,670 | $118 |
| Short return visit (20+ min) | 38 | $3,628 | $76 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 31 | $1,487 | $35 |
| Injection of drug or substance under skin or into muscle | 13 | $487 | $13 |
2020: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 38 | $78,399 | $260 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 160 | $34,924 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 117 | $28,545 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $15,221 | $179 |
| Long return visit (40+ min) | 61 | $14,171 | $128 |
| Return visit (30+ min) | 100 | $13,891 | $89 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $8,274 | $207 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $5,529 | $120 |
| Hemodialysis procedure with physician evaluation | 37 | $5,384 | $66 |
| New patient visit (60+ min) | 15 | $2,680 | $179 |
| New patient visit (45+ min) | 17 | $2,461 | $145 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 39 | $2,408 | $36 |
| Short return visit (20+ min) | 30 | $1,813 | $52 |
2019: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 46 | $85,949 | $253 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 187 | $46,070 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $27,003 | $92 |
| Return visit (30+ min) | 114 | $19,233 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 91 | $17,016 | $175 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 29 | $13,400 | $209 |
| Long return visit (40+ min) | 51 | $12,198 | $130 |
| Hemodialysis procedure with physician evaluation | 58 | $9,147 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $7,014 | $119 |
| Short return visit (20+ min) | 46 | $3,392 | $58 |
| New patient visit (45+ min) | 23 | $3,215 | $140 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 41 | $2,153 | $35 |
| Injection of drug or substance under skin or into muscle | 12 | $588 | $15 |
2018: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 46 | $83,118 | $242 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 200 | $34,576 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 136 | $25,485 | $89 |
| Return visit (30+ min) | 107 | $15,785 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $14,307 | $172 |
| Long return visit (40+ min) | 60 | $12,378 | $115 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 30 | $12,196 | $207 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 56 | $7,311 | $112 |
| Hemodialysis procedure with physician evaluation | 46 | $5,776 | $62 |
| New patient visit (45+ min) | 24 | $3,285 | $137 |
| Short return visit (20+ min) | 42 | $2,861 | $56 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 53 | $1,846 | $34 |
2017: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $84,596 | $248 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 223 | $45,554 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 151 | $31,172 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 97 | $18,271 | $176 |
| Long return visit (40+ min) | 50 | $13,335 | $121 |
| Return visit (30+ min) | 83 | $12,377 | $85 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 24 | $7,590 | $205 |
| Hemodialysis procedure with physician evaluation | 45 | $5,969 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,412 | $113 |
| Short return visit (20+ min) | 52 | $3,718 | $55 |
| Dialysis services, 1 physician visit per month (20 years or older) | 11 | $2,497 | $156 |
| New patient visit (45+ min) | 17 | $2,254 | $133 |
| New patient visit (60+ min) | 12 | $2,176 | $181 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 52 | $2,047 | $34 |
2016: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 52 | $86,282 | $242 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $32,241 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 176 | $29,574 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $20,189 | $171 |
| Return visit (30+ min) | 89 | $12,150 | $86 |
| Long return visit (40+ min) | 47 | $10,433 | $120 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $9,482 | $206 |
| Hemodialysis procedure with physician evaluation | 43 | $6,619 | $62 |
| New patient visit (45+ min) | 29 | $4,063 | $140 |
| Short return visit (20+ min) | 48 | $3,260 | $56 |
| Dialysis procedure including 1 evaluation | 11 | $2,819 | $67 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 51 | $2,222 | $34 |
2015: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 45 | $86,853 | $243 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 185 | $31,198 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 121 | $27,283 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 123 | $25,473 | $172 |
| Return visit (30+ min) | 97 | $15,031 | $90 |
| Long return visit (40+ min) | 40 | $10,868 | $119 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 20 | $7,201 | $206 |
| Hemodialysis procedure with physician evaluation | 45 | $6,223 | $62 |
| Short return visit (20+ min) | 49 | $3,911 | $61 |
| New patient visit (45+ min) | 18 | $2,314 | $129 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 43 | $1,880 | $33 |
2014: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 39 | $68,431 | $244 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 165 | $26,984 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 101 | $25,001 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $19,218 | $172 |
| Long return visit (40+ min) | 52 | $15,259 | $123 |
| Return visit (30+ min) | 86 | $12,736 | $88 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | $7,352 | $199 |
| Hemodialysis procedure with physician evaluation | 37 | $4,965 | $61 |
| New patient visit (60+ min) | 14 | $2,457 | $176 |
| Short return visit (20+ min) | 35 | $2,430 | $58 |
| New patient visit (45+ min) | 11 | $1,602 | $146 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 23 | $939 | $34 |
2013: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 51 | $81,522 | $245 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 210 | $38,729 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 110 | $28,997 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $20,985 | $169 |
| Return visit (30+ min) | 86 | $13,751 | $91 |
| Hemodialysis procedure with physician evaluation | 60 | $12,448 | $61 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 36 | $11,435 | $208 |
| Long return visit (40+ min) | 48 | $9,342 | $121 |
| Dialysis services, 1 physician visit per month (20 years or older) | 14 | $3,875 | $161 |
| Short return visit (20+ min) | 48 | $3,575 | $61 |
| New patient visit (45+ min) | 19 | $2,640 | $139 |
| New patient visit (60+ min) | 12 | $1,925 | $160 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 47 | $1,631 | $33 |
Medicaid work
$115,099 in 2024
Medicaid paid $115,099 for 1,439 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 310 | $48,313 |
| Long return visit (40+ min) | 228 | $20,939 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 312 | $16,621 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 341 | $12,801 |
| Return visit (30+ min) | 148 | $9,388 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 24 | $4,744 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 38 | $1,762 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 25 | $378 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (List separately in addition to code for primary procedure) | 13 | $153 |
| 2024 | 1,439 | 9 | 33 | $115,099 |
| 2023 | 1,255 | 7 | 33 | $112,475 |
| 2022 | 1,183 | 6 | 30 | $96,200 |
| 2021 | 1,253 | 6 | 34 | $70,642 |
| 2020 | 1,290 | 6 | 35 | $53,111 |
| 2019 | 2,326 | 6 | 35 | $62,145 |
| 2018 | 1,469 | 7 | 33 | $58,047 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 310 | $58,400 |
| Long return visit (40+ min) | 180 | $18,154 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 307 | $15,174 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 313 | $11,879 |
| Return visit (30+ min) | 94 | $6,637 |
| 1ST HOSP IP/OBS HIGH 75 | 28 | $1,708 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 23 | $522 |
2022
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 315 | $61,437 |
| Long return visit (40+ min) | 190 | $14,302 |
| Return visit (30+ min) | 171 | $9,563 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 342 | $5,327 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 153 | $4,968 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $603 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 337 | $43,914 |
| Long return visit (40+ min) | 185 | $11,850 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 354 | $6,263 |
| Return visit (30+ min) | 147 | $5,663 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 97 | $2,952 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 133 | $0 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 369 | $39,395 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 384 | $5,480 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 157 | $4,257 |
| Long return visit (40+ min) | 52 | $2,401 |
| Return visit (30+ min) | 61 | $1,577 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 267 | $0 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 378 | $39,813 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 556 | $11,058 |
| Return visit (30+ min) | 148 | $6,138 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 104 | $2,942 |
| 1ST HOSP IP/OBS HIGH 75 | 27 | $2,195 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 1,113 | $0 |
2018
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 340 | $37,570 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 448 | $8,005 |
| Return visit (30+ min) | 171 | $6,263 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 137 | $3,608 |
| Long return visit (40+ min) | 44 | $1,863 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $737 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 315 | $0 |
Drugs they prescribed that Part D paid
$706,299
Pharmacies billed $706,299 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,723) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,317 generic and 406 brand-name prescriptions · $706,299 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rayaldee | 79 | $141,073 | $1,786 |
| Farxiga | 85 | $103,717 | $1,220 |
| Kerendia | 39 | $67,666 | $1,735 |
| Jardiance | 44 | $65,104 | $1,480 |
| Veltassa | 36 | $64,116 | $1,781 |
See all 30 drugs
| Rayaldee | 79 | $141,073 | $1,786 |
| Farxiga | 85 | $103,717 | $1,220 |
| Kerendia | 39 | $67,666 | $1,735 |
| Jardiance | 44 | $65,104 | $1,480 |
| Veltassa | 36 | $64,116 | $1,781 |
| Lokelma | 29 | $44,731 | $1,542 |
| Cinacalcet | 30 | $43,923 | $1,464 |
| Procrit | 23 | $28,491 | $1,239 |
| Renvela | 14 | $23,584 | $1,685 |
| Januvia | 11 | $17,532 | $1,594 |
| Sevelamer Carbonate | 34 | $12,130 | $357 |
| Calcitriol | 281 | $5,788 | $21 |
| Sps | 21 | $5,611 | $267 |
| Valsartan | 133 | $5,309 | $40 |
| Calcium Acetate | 50 | $4,174 | $83 |
| Hydralazine | 61 | $1,604 | $26 |
| Nifedipine Er | 18 | $953 | $53 |
| Amlodipine Besylate | 127 | $744 | $6 |
| Carvedilol | 68 | $715 | $11 |
| Nebivolol | 11 | $596 | $54 |
| Metoprolol | 37 | $511 | $14 |
| Spironolactone | 58 | $477 | $8 |
| Losartan | 62 | $406 | $7 |
| Allopurinol | 41 | $374 | $9 |
| Lisinopril | 48 | $321 | $7 |
| Potassium Chloride | 18 | $292 | $16 |
| Furosemide | 53 | $278 | $5 |
| Metoprolol | 15 | $199 | $13 |
| Famotidine | 11 | $33 | $3 |
| Atorvastatin | 15 | $22 | $1 |
Year by year
| 2024 | 1,723 | 272 | 0% (0) | 24% | $706,299 |
| 2023 | 1,618 | 237 | 0% (0) | None | $717,782 |
| 2022 | 1,457 | 205 | 0% (0) | 25% | $533,164 |
| 2021 | 1,201 | 191 | 0% (0) | None | $333,135 |
| 2020 | 1,118 | 172 | 0% (0) | 26% | $295,279 |
| 2019 | 1,107 | 170 | 0% (0) | 25% | $266,559 |
| 2018 | 1,312 | 169 | 0% (0) | 26% | $309,085 |
| 2017 | 1,388 | 153 | 0% (0) | None | $488,164 |
| 2016 | 1,618 | 147 | 0% (0) | 33% | $607,426 |
| 2015 | 1,673 | 146 | None | None | $525,628 |
| 2014 | 1,402 | 137 | 0% (0) | 41% | $815,230 |
| 2013 | 1,552 | 149 | None | 43% | $398,785 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Farxiga | 109 | $154,551 | $1,418 |
| Rayaldee | 54 | $102,374 | $1,896 |
| Veltassa | 50 | $77,170 | $1,543 |
| Kerendia | 29 | $57,060 | $1,968 |
| Lokelma | 32 | $55,968 | $1,749 |
| Procrit | 32 | $41,208 | $1,288 |
| Cinacalcet | 20 | $25,543 | $1,277 |
| Sevelamer Carbonate | 51 | $21,556 | $423 |
| Retacrit | 16 | $20,008 | $1,251 |
| Sps | 34 | $9,063 | $267 |
| Valsartan | 124 | $7,720 | $62 |
| Calcitriol | 219 | $6,016 | $27 |
| Calcium Acetate | 54 | $5,816 | $108 |
| Clonidine | 13 | $2,526 | $194 |
| Amlodipine Besylate | 130 | $1,957 | $15 |
| Hydralazine | 55 | $1,610 | $29 |
| Losartan | 64 | $1,364 | $21 |
| Metoprolol | 43 | $1,249 | $29 |
| Carvedilol | 68 | $1,236 | $18 |
| Allopurinol | 58 | $1,169 | $20 |
| Nifedipine Er | 13 | $1,127 | $87 |
| Lisinopril | 51 | $808 | $16 |
| Potassium Chloride | 17 | $728 | $43 |
| Furosemide | 42 | $699 | $17 |
| Spironolactone | 47 | $544 | $12 |
2022: 27 drugs
| Farxiga | 98 | $121,335 | $1,238 |
| Rayaldee | 52 | $72,786 | $1,400 |
| Veltassa | 28 | $53,198 | $1,900 |
| Lokelma | 32 | $44,290 | $1,384 |
| Renvela | 14 | $36,126 | $2,580 |
| Cinacalcet | 40 | $28,268 | $707 |
| Procrit | 22 | $26,947 | $1,225 |
| Retacrit | 25 | $23,713 | $949 |
| Kerendia | 18 | $19,010 | $1,056 |
| Sevelamer Carbonate | 59 | $16,423 | $278 |
| Valsartan | 103 | $6,194 | $60 |
| Paricalcitol | 11 | $5,131 | $466 |
| Calcitriol | 191 | $4,542 | $24 |
| Calcium Acetate | 26 | $4,131 | $159 |
| Sps | 11 | $2,152 | $196 |
| Carvedilol | 76 | $1,319 | $17 |
| Allopurinol | 60 | $1,178 | $20 |
| Amlodipine Besylate | 103 | $1,120 | $11 |
| Metoprolol | 37 | $968 | $26 |
| Hydralazine | 45 | $934 | $21 |
| Losartan | 59 | $812 | $14 |
| Potassium Chloride | 20 | $661 | $33 |
| Spironolactone | 41 | $511 | $12 |
| Lisinopril | 39 | $511 | $13 |
| Chlorthalidone | 13 | $506 | $39 |
| Furosemide | 33 | $382 | $12 |
| Metoprolol | 13 | $100 | $8 |
2021: 26 drugs
| Procrit | 41 | $61,952 | $1,511 |
| Lokelma | 25 | $37,142 | $1,486 |
| Veltassa | 27 | $33,111 | $1,226 |
| Cinacalcet | 27 | $26,509 | $982 |
| Retacrit | 30 | $19,976 | $666 |
| Renvela | 12 | $15,829 | $1,319 |
| Sevelamer Carbonate | 54 | $9,784 | $181 |
| Paricalcitol | 21 | $6,198 | $295 |
| Calcitriol | 162 | $5,263 | $32 |
| Calcium Acetate | 27 | $3,997 | $148 |
| Valsartan | 33 | $1,790 | $54 |
| Diltiazem 24hr Er (Cd) | 14 | $1,555 | $111 |
| Metoprolol | 57 | $1,277 | $22 |
| Losartan | 71 | $1,040 | $15 |
| Allopurinol | 49 | $914 | $19 |
| Carvedilol | 52 | $788 | $15 |
| Hydralazine | 35 | $706 | $20 |
| Gentamicin Sulfate | 15 | $666 | $44 |
| Amlodipine Besylate | 82 | $646 | $8 |
| Potassium Chloride | 16 | $542 | $34 |
| Diltiazem 24hr Er | 16 | $317 | $20 |
| Spironolactone | 31 | $207 | $7 |
| Furosemide | 36 | $182 | $5 |
| Prednisone | 13 | $131 | $10 |
| Metoprolol | 14 | $130 | $9 |
| Lisinopril | 22 | $109 | $5 |
2020: 24 drugs
| Rayaldee | 19 | $41,323 | $2,175 |
| Renvela | 27 | $38,977 | $1,444 |
| Lokelma | 25 | $32,934 | $1,317 |
| Cinacalcet | 41 | $30,246 | $738 |
| Procrit | 22 | $27,152 | $1,234 |
| Veltassa | 13 | $19,385 | $1,491 |
| Sevelamer Carbonate | 46 | $12,324 | $268 |
| Retacrit | 22 | $9,931 | $451 |
| Bystolic | 21 | $9,282 | $442 |
| Prosol | 52 | $5,943 | $114 |
| Calcium Acetate | 33 | $4,550 | $138 |
| Paricalcitol | 29 | $4,383 | $151 |
| Calcitriol | 148 | $3,659 | $25 |
| Losartan | 82 | $956 | $12 |
| Potassium Chloride | 17 | $805 | $47 |
| Metoprolol | 30 | $774 | $26 |
| Allopurinol | 54 | $634 | $12 |
| Amlodipine Besylate | 99 | $598 | $6 |
| Olmesartan Medoxomil | 12 | $560 | $47 |
| Carvedilol | 50 | $455 | $9 |
| Hydralazine | 23 | $451 | $20 |
| Spironolactone | 36 | $314 | $9 |
| Furosemide | 34 | $287 | $8 |
| Lisinopril | 17 | $151 | $9 |
2019: 25 drugs
| Renvela | 40 | $54,691 | $1,367 |
| Veltassa | 40 | $50,631 | $1,266 |
| Rayaldee | 25 | $31,242 | $1,250 |
| Procrit | 15 | $20,896 | $1,393 |
| Sevelamer Carbonate | 44 | $17,236 | $392 |
| Cinacalcet | 13 | $10,404 | $800 |
| Sensipar | 12 | $9,260 | $772 |
| Bystolic | 22 | $8,477 | $385 |
| Paricalcitol | 36 | $7,905 | $220 |
| Prosol | 50 | $5,679 | $114 |
| Calcitriol | 143 | $3,975 | $28 |
| Calcium Acetate | 27 | $2,977 | $110 |
| Olmesartan Medoxomil | 28 | $2,683 | $96 |
| Metoprolol | 46 | $1,584 | $34 |
| Carvedilol | 61 | $827 | $14 |
| Amlodipine Besylate | 98 | $792 | $8 |
| Allopurinol | 51 | $686 | $13 |
| Hydralazine | 27 | $639 | $24 |
| Losartan | 51 | $550 | $11 |
| Gentamicin Sulfate | 11 | $412 | $37 |
| Furosemide | 60 | $395 | $7 |
| Potassium Chloride | 11 | $335 | $30 |
| Lisinopril | 18 | $194 | $11 |
| Spironolactone | 16 | $183 | $11 |
| Atorvastatin | 12 | $100 | $8 |
2018: 29 drugs
| Renvela | 74 | $109,165 | $1,475 |
| Sevelamer Carbonate | 50 | $36,303 | $726 |
| Sensipar | 24 | $23,958 | $998 |
| Veltassa | 16 | $21,451 | $1,341 |
| Procrit | 15 | $18,476 | $1,232 |
| Paricalcitol | 29 | $8,013 | $276 |
| Bystolic | 19 | $6,729 | $354 |
| Prosol | 52 | $5,854 | $113 |
| Calcium Acetate | 65 | $4,691 | $72 |
| Calcitriol | 131 | $4,654 | $36 |
| Metoprolol | 38 | $1,865 | $49 |
| Kionex | 15 | $1,675 | $112 |
| Valsartan | 45 | $1,618 | $36 |
| Sodium Polystyrene Sulfonate | 13 | $1,376 | $106 |
| Olmesartan Medoxomil | 28 | $1,349 | $48 |
| Amlodipine Besylate | 113 | $937 | $8 |
| Carvedilol | 102 | $884 | $9 |
| Hydralazine | 44 | $764 | $17 |
| Midodrine | 11 | $634 | $58 |
| Allopurinol | 37 | $414 | $11 |
| Furosemide | 54 | $271 | $5 |
| Losartan | 32 | $265 | $8 |
| Lisinopril | 40 | $261 | $7 |
| Spironolactone | 22 | $188 | $9 |
| Pravastatin | 15 | $178 | $12 |
| Atorvastatin | 14 | $131 | $9 |
| Lactulose | 11 | $108 | $10 |
| Fluticasone Propionate | 11 | $100 | $9 |
| Clopidogrel | 12 | $14 | $1 |
2017: 31 drugs
| Renvela | 108 | $205,737 | $1,905 |
| Sensipar | 62 | $89,871 | $1,450 |
| Procrit | 16 | $26,773 | $1,673 |
| Velphoro | 11 | $26,628 | $2,421 |
| Paricalcitol | 59 | $20,943 | $355 |
| Fosrenol | 13 | $13,956 | $1,074 |
| Uloric | 15 | $9,730 | $649 |
| Veltassa | 14 | $8,956 | $640 |
| Calcium Acetate | 76 | $8,004 | $105 |
| Prosol | 52 | $6,107 | $117 |
| Bystolic | 20 | $5,186 | $259 |
| Calcitriol | 105 | $5,114 | $49 |
| Metoprolol | 59 | $2,392 | $41 |
| Kionex | 23 | $2,378 | $103 |
| Sps | 15 | $1,689 | $113 |
| Valsartan | 50 | $1,536 | $31 |
| Amlodipine Besylate | 122 | $674 | $6 |
| Carvedilol | 80 | $628 | $8 |
| Hydralazine | 25 | $504 | $20 |
| Allopurinol | 41 | $494 | $12 |
| Losartan | 33 | $318 | $10 |
| Minoxidil | 14 | $295 | $21 |
| Pravastatin | 16 | $247 | $15 |
| Prednisone | 13 | $219 | $17 |
| Lisinopril | 29 | $144 | $5 |
| Furosemide | 45 | $126 | $3 |
| Atorvastatin | 18 | $115 | $6 |
| Famotidine | 12 | $78 | $6 |
| Metoprolol | 19 | $75 | $4 |
| Pantoprazole | 12 | $62 | $5 |
| Simvastatin | 13 | $42 | $3 |
2016: 29 drugs
| Renvela | 164 | $301,138 | $1,836 |
| Sensipar | 98 | $144,964 | $1,479 |
| Procrit | 13 | $22,827 | $1,756 |
| Paricalcitol | 59 | $19,348 | $328 |
| Uloric | 25 | $13,141 | $526 |
| Doxercalciferol | 24 | $12,342 | $514 |
| Calcium Acetate | 67 | $6,966 | $104 |
| Valsartan | 59 | $6,735 | $114 |
| Calcitriol | 133 | $5,403 | $41 |
| Bystolic | 19 | $4,266 | $225 |
| Kionex | 20 | $3,683 | $184 |
| Metoprolol | 65 | $2,374 | $37 |
| Carvedilol | 103 | $860 | $8 |
| Amlodipine Besylate | 141 | $853 | $6 |
| Allopurinol | 58 | $825 | $14 |
| Nifedipine Er | 23 | $739 | $32 |
| Prochlorperazine Maleate | 12 | $696 | $58 |
| Pravastatin | 30 | $494 | $16 |
| Hydralazine | 28 | $463 | $17 |
| Bd Ultra-Fine Pen Needle | 11 | $444 | $40 |
| Omeprazole | 18 | $338 | $19 |
| Losartan | 22 | $271 | $12 |
| Lisinopril | 48 | $257 | $5 |
| Metoprolol | 38 | $238 | $6 |
| Furosemide | 47 | $215 | $5 |
| Atorvastatin | 18 | $141 | $8 |
| Famotidine | 11 | $101 | $9 |
| Pantoprazole | 15 | $75 | $5 |
| Clonidine | 13 | $36 | $3 |
2015: 33 drugs
| Renvela | 157 | $247,245 | $1,575 |
| Sensipar | 120 | $138,425 | $1,154 |
| Fosrenol | 25 | $21,258 | $850 |
| Procrit | 13 | $19,127 | $1,471 |
| Paricalcitol | 45 | $16,817 | $374 |
| Doxercalciferol | 15 | $11,675 | $778 |
| Uloric | 22 | $9,435 | $429 |
| Calcium Acetate | 62 | $6,161 | $99 |
| Calcitriol | 138 | $4,892 | $35 |
| Bystolic | 15 | $3,987 | $266 |
| Kionex | 23 | $3,708 | $161 |
| Valsartan | 32 | $3,426 | $107 |
| Diovan | 11 | $3,074 | $279 |
| Metoprolol | 74 | $2,722 | $37 |
| Nifedipine Er | 34 | $1,540 | $45 |
| Allopurinol | 74 | $973 | $13 |
| Amlodipine Besylate | 136 | $869 | $6 |
| Carvedilol | 91 | $619 | $7 |
| Pravastatin | 24 | $553 | $23 |
| Lisinopril | 64 | $373 | $6 |
| Omeprazole | 21 | $358 | $17 |
| Furosemide | 61 | $293 | $5 |
| Levothyroxine | 22 | $285 | $13 |
| Hydralazine | 28 | $282 | $10 |
| Isosorbide Mononitrate Er | 13 | $224 | $17 |
| Atorvastatin | 24 | $206 | $9 |
| Metoprolol | 19 | $152 | $8 |
| Losartan | 21 | $143 | $7 |
| Simvastatin | 28 | $119 | $4 |
| Isoniazid | 11 | $116 | $11 |
| Pantoprazole | 15 | $97 | $6 |
| Famotidine | 11 | $79 | $7 |
| Minoxidil | 13 | $68 | $5 |
2014: 30 drugs
| H.P. Acthar | 12 | $388,471 | $32,373 |
| Renvela | 104 | $138,461 | $1,331 |
| Sensipar | 105 | $123,715 | $1,178 |
| Doxercalciferol | 22 | $21,004 | $955 |
| Paricalcitol | 38 | $20,336 | $535 |
| Procrit | 14 | $19,655 | $1,404 |
| Zemplar | 18 | $17,616 | $979 |
| Diovan | 50 | $14,373 | $287 |
| Calcitriol | 127 | $7,446 | $59 |
| Calcium Acetate | 41 | $7,223 | $176 |
| Uloric | 11 | $5,076 | $461 |
| Metoprolol | 66 | $2,762 | $42 |
| Kionex | 15 | $2,717 | $181 |
| Nifedipine Er | 26 | $1,515 | $58 |
| Amlodipine Besylate | 117 | $830 | $7 |
| Allopurinol | 74 | $586 | $8 |
| Carvedilol | 60 | $580 | $10 |
| Hydralazine | 20 | $442 | $22 |
| Furosemide | 68 | $412 | $6 |
| Lisinopril | 45 | $316 | $7 |
| Omeprazole | 16 | $256 | $16 |
| Isosorbide Mononitrate Er | 11 | $194 | $18 |
| Benazepril | 29 | $185 | $6 |
| Atorvastatin | 18 | $182 | $10 |
| Metoprolol | 17 | $158 | $9 |
| Famotidine | 19 | $155 | $8 |
| Losartan | 19 | $152 | $8 |
| Levothyroxine | 12 | $130 | $11 |
| Simvastatin | 16 | $89 | $6 |
| Minoxidil | 19 | $87 | $5 |
2013: 32 drugs
| Renvela | 131 | $141,345 | $1,079 |
| Sensipar | 100 | $74,258 | $743 |
| Zemplar | 67 | $32,603 | $487 |
| Hectorol | 39 | $27,267 | $699 |
| Procrit | 26 | $19,555 | $752 |
| Diovan | 62 | $15,407 | $249 |
| Tacrolimus | 11 | $9,026 | $821 |
| Calcitriol | 124 | $8,426 | $68 |
| Paricalcitol | 16 | $7,958 | $497 |
| Calcium Acetate | 26 | $6,244 | $240 |
| Benicar | 12 | $4,549 | $379 |
| Metoprolol | 69 | $3,623 | $53 |
| Kionex | 13 | $2,246 | $173 |
| Nifedipine Er | 33 | $1,772 | $54 |
| Amlodipine Besylate | 133 | $1,298 | $10 |
| Sps | 15 | $1,244 | $83 |
| Hydralazine | 31 | $967 | $31 |
| Carvedilol | 81 | $906 | $11 |
| Minoxidil | 45 | $745 | $17 |
| Allopurinol | 65 | $514 | $8 |
| Diltiazem Er | 12 | $502 | $42 |
| Losartan | 17 | $486 | $29 |
| Megestrol Acetate | 12 | $485 | $40 |
| Furosemide | 69 | $405 | $6 |
| Pravastatin | 13 | $313 | $24 |
| Metoprolol | 31 | $233 | $8 |
| Lisinopril | 23 | $228 | $10 |
| Isosorbide Mononitrate Er | 12 | $204 | $17 |
| Clonidine | 14 | $198 | $14 |
| Levothyroxine | 12 | $109 | $9 |
| Simvastatin | 12 | $60 | $5 |
| Hydrochlorothiazide | 12 | $48 | $4 |
Money from drug and device companies
$2,191 in 2025
| 2025 | 21 | 97 | None | $2,191 |
| 2024 | 19 | 77 | None | $2,005 |
| 2023 | 19 | 88 | None | $1,754 |
| 2022 | 15 | 55 | None | $1,377 |
| 2021 | 11 | 37 | $200 | $1,120 |
| 2020 | 9 | 29 | None | $527 |
| 2019 | 9 | 38 | None | $896 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Fabhalta | $426 | 23 payments
|
| Novo Nordisk | Ozempic | $311 | 8 payments
|
| Fresenius USA Marketing | Velphoro | $180 | 9 payments
|
| Calliditas Therapeutics US | Tarpeyo | $168 | 11 payments
|
| GlaxoSmithKline | Benlysta | $166 | 7 payments
|
| Travere Therapeutics | Filspari | $164 | 2 payments
|
See all 96 published payments
| Fresenius USA Marketing | Meals · 2025-12-19 | Velphoro | $23 |
| GlaxoSmithKline | Meals · 2025-12-18 | Benlysta | $21 |
| Apellis Pharmaceuticals | Meals · 2025-12-17 | Empaveli | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-16 | Farxiga | $23 |
| Novartis Pharmaceuticals | Meals · 2025-12-15 | Fabhalta | $18 |
| Calliditas Therapeutics US | Meals · 2025-12-12 | Tarpeyo | $11 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-11 | Kerendia | $25 |
| Ardelyx | Meals · 2025-11-17 | Ibsrela | $24 |
| Mallinckrodt Hospital Products | Meals · 2025-11-14 | Acthar | $29 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Fabhalta | $14 |
| Travere Therapeutics | Meals · 2025-11-12 | Filspari | $130 |
| Fresenius USA Marketing | Meals · 2025-11-12 | Velphoro | $24 |
| Novartis Pharmaceuticals | Meals · 2025-10-22 | Fabhalta | $26 |
| Calliditas Therapeutics US | Meals · 2025-10-20 | Tarpeyo | $19 |
| Novartis Pharmaceuticals | Meals · 2025-10-17 | Fabhalta | $23 |
| GlaxoSmithKline | Meals · 2025-10-16 | Benlysta | $28 |
| Mallinckrodt Hospital Products | Meals · 2025-10-15 | Acthar | $20 |
| Fresenius USA Marketing | Meals · 2025-10-15 | Velphoro | $24 |
| Amgen | Meals · 2025-10-13 | Krystexxa | $60 |
| Calliditas Therapeutics US | Meals · 2025-10-10 | Tarpeyo | $32 |
| Calliditas Therapeutics US | Meals · 2025-10-09 | Tarpeyo | $3 |
| Novo Nordisk | Meals · 2025-10-02 | Wegovy | $22 |
| Novo Nordisk | Meals · 2025-10-01 | Wegovy | $10 |
| Novartis Pharmaceuticals | Meals · 2025-09-22 | Fabhalta | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-19 | Farxiga | $20 |
| Novartis Pharmaceuticals | Meals · 2025-09-18 | Fabhalta | $14 |
| Fresenius USA Marketing | Meals · 2025-09-15 | Velphoro | $18 |
| Calliditas Therapeutics US | Meals · 2025-09-12 | Tarpeyo | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-11 | Jardiance | $18 |
| Amgen | Meals · 2025-09-11 | Krystexxa | $28 |
| Veloxis Pharmaceuticals | Meals · 2025-09-08 | Envarsus | $20 |
| Novartis Pharmaceuticals | Meals · 2025-09-05 | Fabhalta | $31 |
| Novartis Pharmaceuticals | Meals · 2025-09-04 | Fabhalta | $31 |
| Calliditas Therapeutics US | Meals · 2025-08-28 | Tarpeyo | $10 |
| GlaxoSmithKline | Meals · 2025-08-22 | Benlysta | $26 |
| Novo Nordisk | Meals · 2025-08-19 | Wegovy | $10 |
| Ardelyx | Meals · 2025-08-06 | Ibsrela | $27 |
| Calliditas Therapeutics US | Meals · 2025-08-04 | Tarpeyo | $11 |
| Fresenius USA Marketing | Meals · 2025-08-04 | Velphoro | $1 |
| Fresenius USA Marketing | Meals · 2025-08-04 | Velphoro | $22 |
| Novartis Pharmaceuticals | Meals · 2025-07-28 | Fabhalta | $18 |
| Novartis Pharmaceuticals | Meals · 2025-07-11 | Fabhalta | $23 |
| Calliditas Therapeutics US | Meals · 2025-07-11 | Tarpeyo | $14 |
| Otsuka America Pharmaceutical | Meals · 2025-07-09 | Jynarque | $31 |
| Aurinia Pharma U.S. | Meals · 2025-07-08 | Lupkynis | $19 |
| Vifor Pharma | Meals · 2025-06-26 | Veltassa | $24 |
| Novartis Pharmaceuticals | Meals · 2025-06-25 | Fabhalta | $31 |
| Novartis Pharmaceuticals | Meals · 2025-06-25 | Fabhalta | $3 |
| Apellis Pharmaceuticals | Meals · 2025-06-23 | None | $16 |
| Calliditas Therapeutics US | Meals · 2025-06-20 | Tarpeyo | $12 |
| Ardelyx | Meals · 2025-06-18 | Ibsrela | $22 |
| Novartis Pharmaceuticals | Meals · 2025-06-13 | Fabhalta | $27 |
| Novartis Pharmaceuticals | Meals · 2025-06-05 | Fabhalta | $16 |
| Novartis Pharmaceuticals | Meals · 2025-06-05 | Fabhalta | $5 |
| Mallinckrodt Hospital Products | Meals · 2025-06-05 | Acthar | $15 |
| GlaxoSmithKline | Meals · 2025-06-04 | Benlysta | $29 |
| Fresenius USA Marketing | Meals · 2025-06-02 | Velphoro | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-24 | Farxiga | $15 |
| GlaxoSmithKline | Meals · 2025-05-19 | Benlysta | $21 |
| Calliditas Therapeutics US | Meals · 2025-05-19 | Tarpeyo | $10 |
| Novartis Pharmaceuticals | Meals · 2025-04-21 | Fabhalta | $4 |
| Novartis Pharmaceuticals | Meals · 2025-04-21 | Fabhalta | $21 |
| Novartis Pharmaceuticals | Meals · 2025-04-18 | Fabhalta | $12 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-18 | Farxiga | $14 |
| Amgen | Meals · 2025-04-18 | Krystexxa | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-04-17 | Jynarque | $27 |
| Novo Nordisk | Meals · 2025-04-04 | Wegovy | $16 |
| GlaxoSmithKline | Meals · 2025-04-02 | Benlysta | $25 |
| Fresenius USA Marketing | Meals · 2025-03-31 | Velphoro | $23 |
| Novo Nordisk | Meals · 2025-03-28 | Wegovy | $96 |
| Novartis Pharmaceuticals | Meals · 2025-03-24 | Fabhalta | $18 |
| Novartis Pharmaceuticals | Meals · 2025-03-24 | Fabhalta | $2 |
| ANI Pharmaceuticals | Meals · 2025-03-22 | Purified Cortrophin Gel | $25 |
| Lilly USA | Meals · 2025-03-19 | Mounjaro | $17 |
| Otsuka America Pharmaceutical | Meals · 2025-03-19 | Jynarque | $21 |
| Fresenius USA Marketing | Meals · 2025-03-19 | Velphoro | $23 |
| Novo Nordisk | Meals · 2025-03-18 | Ozempic | $124 |
| Novo Nordisk | Meals · 2025-03-18 | Ozempic | $15 |
| Novartis Pharmaceuticals | Meals · 2025-03-18 | Fabhalta | $11 |
| Amgen | Meals · 2025-03-17 | Krystexxa | $11 |
| Ardelyx | Meals · 2025-03-14 | Ibsrela | $23 |
| OPKO Pharmaceuticals | Education · 2025-03-12 | Rayaldee | $14 |
| Travere Therapeutics | Meals · 2025-03-05 | None | $34 |
| Novo Nordisk | Meals · 2025-03-01 | Ozempic | $18 |
| Novartis Pharmaceuticals | Meals · 2025-02-21 | Fabhalta | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-14 | Farxiga | $15 |
| Novartis Pharmaceuticals | Meals · 2025-02-13 | Fabhalta | $33 |
| Mallinckrodt Hospital Products | Meals · 2025-02-07 | Acthar | $21 |
| Kyowa Kirin | Meals · 2025-02-07 | Crysvita | $15 |
| GlaxoSmithKline | Meals · 2025-02-05 | Benlysta | $15 |
| Amgen | Meals · 2025-02-03 | Krystexxa | $25 |
| Calliditas Therapeutics US | Meals · 2025-01-23 | Tarpeyo | $27 |
| OPKO Pharmaceuticals | Education · 2025-01-22 | Rayaldee | $20 |
| Mallinckrodt Hospital Products | Meals · 2025-01-11 | Acthar | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-08 | Jardiance | $15 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-08 | Kerendia | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,005
| Travere Therapeutics | None | $270 | 2 payments
|
| Novo Nordisk | Wegovy | $248 | 9 payments
|
| Amgen | Krystexxa | $243 | 11 payments
|
| Ardelyx | Xphozah 30 Mg | $200 | 6 payments
|
| Aurinia Pharma U.S. | Lupkynis | $186 | 7 payments
|
| Novartis Pharmaceuticals | Fabhalta | $178 | 9 payments
|
| Mallinckrodt Hospital Products | Acthar | $98 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $87 | 5 payments
|
| Fresenius USA Marketing | Velphoro | $84 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $73 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $70 | 3 payments
|
| Calliditas Therapeutics US | Tarpeyo | $69 | 3 payments
|
| OPKO Pharmaceuticals | Rayaldee | $56 | 3 payments
|
| Vifor Pharma | Veltassa | $47 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $27 | 2 payments
|
| Lilly USA | Jardiance | $20 | 1 payment
|
| GlaxoSmithKline | Jesduvroq | $19 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $15 | 1 payment
|
| Veloxis Pharmaceuticals | Envarsus | $15 | 1 payment
|
2023: $1,754
| AstraZeneca Pharmaceuticals LP | Farxiga | $380 | 11 payments
|
| Novo Nordisk | Rybelsus | $264 | 13 payments
|
| GlaxoSmithKline | Benlysta | $205 | 12 payments
|
| Vifor Pharma | Veltassa | $131 | 5 payments
|
| Calliditas Therapeutics US | Tarpeyo | $98 | 5 payments
|
| Genzyme | Fabrazyme | $86 | 4 payments
|
| Horizon Therapeutics plc | Krystexxa | $78 | 4 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $72 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $69 | 2 payments
|
| Electromed | Smartvest | $68 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $62 | 3 payments
|
| Travere Therapeutics | None | $50 | 5 payments
|
| OPKO Pharmaceuticals | Rayaldee | $49 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $30 | 1 payment
|
| Amgen | Aranesp | $26 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $25 | 1 payment
|
| Novartis Pharmaceuticals | None | $24 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $22 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $14 | 1 payment
|
2022: $1,377
| AstraZeneca Pharmaceuticals LP | Tezspire | $241 | 6 payments
|
| Vifor Pharma | Veltassa | $217 | 9 payments
|
| Mallinckrodt Hospital Products | Acthar | $176 | 5 payments
|
| Aurinia Pharma U.S. | Lupkynis | $170 | 5 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $141 | 3 payments
|
| OPKO Pharmaceuticals | Rayaldee | $84 | 4 payments
|
| GlaxoSmithKline | Benlysta | $70 | 3 payments
|
| Exeltis USA | Purified Cortrophin Gel | $57 | 3 payments
|
| Amgen | Parsabiv | $51 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $48 | 3 payments
|
| Calliditas Therapeutics US | Tarpeyo | $37 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $33 | 2 payments
|
| Novo Nordisk | Rybelsus | $18 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $17 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $17 | 1 payment
|
2021: $1,120
| AstraZeneca Pharmaceuticals LP | Lokelma | $293 | 8 payments
|
| Vifor Pharma | Veltassa | $200 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $185 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $111 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $89 | 5 payments
|
| Fresenius USA Marketing | Velphoro | $80 | 4 payments
|
| Horizon Therapeutics plc | Krystexxa | $70 | 4 payments
|
| Amgen | Parsabiv | $33 | 1 payment
|
| Akebia Therapeutics | Auryxia | $23 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $15 | 1 payment
|
2020: $527
| AstraZeneca Pharmaceuticals LP | Lokelma | $195 | 11 payments
|
| Otsuka America Pharmaceutical | Jynarque | $69 | 3 payments
|
| Akebia Therapeutics | Auryxia | $63 | 3 payments
|
| Relypsa | Veltassa | $59 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $39 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $31 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $31 | 2 payments
|
| GlaxoSmithKline | Benlysta | $24 | 1 payment
|
| Daiichi Sankyo | Injectafer | $15 | 1 payment
|
2019: $896
| AstraZeneca Pharmaceuticals LP | Lokelma | $273 | 10 payments
|
| Relypsa | Veltassa | $186 | 8 payments
|
| Alexion Pharmaceuticals | Soliris | $137 | 2 payments
|
| Genzyme | Fabry-Disease | $61 | 3 payments
|
| Amgen | Parsabiv | $56 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $54 | 3 payments
|
| Daiichi Sankyo | Injectafer | $50 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $44 | 3 payments
|
| Mallinckrodt Enterprises | Acthar | $37 | 2 payments
|
Professional record
- NPI
- 1053359356
- Licence
- CA A065315California A65315: Current · expires 2028-01-31
- Trained
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 1996 · 30 years ago
- Group
- West Coast Kidney
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A653150
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 1999 Mowry Ave, Suite R, Fremont, CA, 94538
- NPI first listed
- 2006-06-02
- NPI last updated
- 2022-11-27
- NPI record certified
- 2022-11-27
This is when the NPI record was last certified, not a medical board exam.